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Abstract
Rare disease variants are receiving increasing importance in the past few years
as the potential cause for many complex diseases, after the common disease
variants failed to explain a large part of the missing heritability. With the
advancement in sequencing techniques as well as computational capabilities,
statistical methodology for analyzing rare variants is now a hot topic, especially in
case-control association studies.
In this thesis, we initially present two related statistical methodologies designed
for case-control studies to predict the number of common and rare variants in a
particular genomic region underlying the complex disease. Genome-wide
association studies are nowadays routinely performed to identify a few putative
marker loci or a candidate region for further analysis. These methods are designed
to work with SNP data on such a genomic region highlighted by GWAS studies for
potential disease variants. The fundamental idea is to use Bayesian methodology
to obtain bivariate posterior distributions on counts of common and rare variants.
While the ﬁrst method uses randomly generated (minimal) ancestral recombination
graphs, the second method uses ensemble clustering method to explore the space
of genealogical trees that represent the inherent structure in the test subjects.
In contrast to the aforesaid methods which work with SNP data, the third
chapter deals with next-generation sequencing data to detect the presence of rare
variants in a genomic region. We present a non-parametric statistical methodology
for rare variant association testing, using the well-known Kolmogorov-Smirnov
framework adapted for genetic data. it is a fast, model-free robust statistic,
designed for situations where both deleterious and protective variants are present.
It is also unique in utilizing the variant locations in the test statistic.
iii
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Is it rare or common?
Many Genome-Wide Association Studies (GWAS) have signals with
unknown etiology. This paper addresses the question — is such an association
signal caused by rare or common variants that lead to increased disease risk? For a
genomic region implicated by a GWAS, we use Single Nucleotide Polymorphism
(SNP) data in a case-control setting to predict how many common or rare variants
there are, using a Bayesian analysis. Our objective is to compute posterior
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probabilities for conﬁgurations of rare and/or common variants. We use an
extension of coalescent trees — the Ancestral Recombination Graphs (ARG) — to
model the genealogical history of the samples based on marker data. As we expect
SNPs to be in Linkage Disequilibrium (LD) with common disease variants, we can
expect the trees to reﬂect on the type of variants. To demonstrate the application,
we apply our method to candidate gene sequencing data from a German
case-control study on nonsyndromic cleft lip with or without cleft palate
(NSCL/P).
1.1 Introduction
The Common-Disease-Common-Variant (CDCV) hypothesis [Balding et al., 2007]
extended the simple model of one-gene-one-disease applicable only to Mendelian
disorders, the notion of common disease variants being that a few common
variants underly a common disease by leading to increased disease susceptibility.
Common variants were deﬁned as variants with > 5% Minor Allele Frequency
(MAF). But as common variants could not explain a large part of the heritability
for many common diseases, the rare variants hypothesis [Bodmer and Bonilla,
2008] [Schork et al., 2009] was put forward as an explanation [Dickson et al., 2010].
As rare variants have very low LD with the SNP markers typically used for
GWAS, such studies are generally under-powered to detect the presence of rare
disease variants [Asimit and Zeggini, 2010]. So, while still using the SNP data, we
aim to answer a fundamental question — does this genomic region contain rare
variants for increasing disease risk?
If we answer this correctly, then we can either continue doing SNP association
studies if only common disease variants are present, or go into sequencing studies
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to detect those rare disease variants. Thus, it seems that a proper answer would be
to predict the number of common and rare disease variants in that region from the
data. More generally, we will provide a posterior distribution of the number of
common and rare variants in the region.
We suggest that the SNP data does in fact contain information about this
problem. It is commonly known that SNPs contain useful information about the
genealogical history of the samples [Balding et al., 2007], which is used to construct
the genealogical tree on which the samples are arranged. The common variants
will shape the coarser structure of the tree, while the rare mutations will come into
play in the lower branches — how the aﬀected and unaﬀected are clustered in the
lower subtrees will tell us if there are some rare disease variants for those group of
subjects. The diagram in the next section illustrate two such scenarios.
Our Bayesian approach is the following — we want to obtain posterior
probabilities for having diﬀerent conﬁgurations of rare and/or common disease
variants. To do so, we use SNP data to generate min-ARG’s [Wu, 2008] (an ARG
[Griﬃths and Marjoram, 1996] with minimum number of recombinations) to model
the genealogical history of the sample, without regard to their case-control status.
On these trees, to perform a Monte Carlo integration, we generate diﬀerent
conﬁgurations of disease mutations, and calculate the likelihood of the observed
disease status. That is then coupled with priors to generate the posterior
distribution. To illustrate, we apply our method to a real dataset, and observe
that the posterior mode indicates the presence a few rare variants — it is discussed
in detail in the real data analysis section. A ﬂowchart showing the steps is
presented in the next section, and a summarized algorithm is presented at the end
of the methods section. We also explain the workings of the method by a toy
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example presented later.
This method can be thought as an extension to the analysis in [Zöllner and
Pritchard, 2005] or [Morris et al., 2002], where a single disease variant (which is
unobserved) within one of the SNP-intervals with the highest posterior probability
was detected. (Similarly, we too assume that the Disease Susceptibility Loci (DSL)
are not the SNP markers themselves.) Here, we allow for multiple disease variants,
both common and rare. Moreover, we want to make an overall conclusion
regarding presence or absence of rare variants, so we aggregate the common and
rare variants by not trying to determine their location within the gene segment
(which would get particularly diﬃcult for rare variants).
1.2 Materials and Methods
The genealogical tree has been a common approach [Balding et al., 2007] to model
the ancestral history of a set of individuals. It is generally accepted [Zöllner and
Pritchard, 2005], [Gusﬁeld et al., 2004] that the ARGs are good approximations of
the true unknown genealogy for case-control data when we have suﬃcient number
of SNPs. The purpose of using them is to distinguish excess sharing of disease
allele from allele sharing due to relatedness. In this way, the genealogical tree
presents the information in the marker SNPs to the case-control association study,
thereby increasing eﬃciency.
In the following diagram (ﬁgure 1.1), we illustrate the hypothetical situation of
two (complex) diseases via two diﬀerent genealogical trees, one being driven by a
common variant and the other by rare variants.
4
 Common variant 
Moderate 
penetrance 
Phenocopy 
 
Rare variants 
  High 
penetrance 
Figure 1.1: Two contrasting scenarios where a complex disease is caused by either
a common variant or two rare variants.
This distinction between common and rare variants is driven largely by the
disease model that we will specify, because the analysis certainly depends on how
we deﬁne those variants and their eﬀects. We specify all the components of the
disease model while describing the likelihood, which has three main components.
After the likelihood, we deﬁne the priors to be used in conjunction, and then show
the steps to compute the posterior. It is important to remember that, as the ﬁnal
posterior probability, we are interested in the presence or absence of variants,
rather than their locations. We explain our method through the ﬂowchart on the
next page.
1.2.1 Flowchart of the Method
A ﬂowchart (ﬁgure 2.1) illustrating the steps of our method is presented here. It is
the diagrammatic representation of the algorithm in section 2.2.4. Here, we show
that, at ﬁrst, genealogical trees (actually, AR graphs) are generated from the SNP
genotype (phased) data. Then, disease information is added for the subjects, and
the disease likelihood is modeled, for which we simulate potential disease
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mutations at diﬀerent branches of the tree. Using all these, the likelihood is
computed, and then using appropriate priors, the posterior is calculated. The
posterior is aggregated over simulated trees and mutations to give the ﬁnal
posterior distribution of rare and common variant counts.
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Figure 1.2: Flowchart for the algorithm.
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1.2.2 Bayesian Analysis
[Morris et al., 2002], [Zöllner and Pritchard, 2005] perform Bayesian analysis to
obtain posterior probabilities of of the SNPs being (in LD with) the true DSLs. In
the ﬁrst step, they use the SNP genotype data (G) to generate possible ARGs (T )
from the posterior P (T j G). In the next step, they evaluate posterior probabilities
of the disease loci (x) given observed disease phenotypes () and the tree
structure, i.e. P (x j ; T ). The locus with the highest posterior probability can
then be reported.
Our Bayesian analysis, while along the lines of [Zöllner and Pritchard, 2005],
extends to complex diseases by allowing multiple DSLs with diﬀerent penetrance.
So, instead of a single DSL, we evaluate the posterior probability of a particular
conﬁguration of DSLs. Then, we evaluate posterior probabilities corresponding to
counts of rare and common variants by aggregating over such posteriors.
Thus, instead of a single location, the vector x now contains all the information
about (simulated) disease-susceptible mutations in the gene — the locations of the
mutations, type of the mutation, as well as the allele at that locus. This x leads to
a count of common and rare variants — denoted by the tuple N = (Nc; Nr). We
can obtain P (N) by aggregating over P (x), and the posterior probability of the
counts — P (N j ; T ) is what we will be interested in.
1.2.3 The Likelihood
The likelihood has three terms in all — ﬁrst, the probabilities of the minARGs
given the SNP genotypes, P (T j G), secondly, the probabilities of the disease
mutations occurring on a tree, P (x j T ), and ﬁnally, the disease probabilities given
the disease mutations, P ( j x;M). It will also include the modeling parameters,
8
which we discuss later.
We will explicitly mention the disease model M , which includes models for the
disease probabilities given the mutations, and involves models for penetrance,
epistasis, phenocopy etc. In the initial stages of our calculations we keep the model
M , as a conditional term, to clearly identify situations where those disease
modeling assumptions play a role. We can later omit the term, as we consider it
ﬁxed.
Modeling the Tree
While modeling the tree, a simple top-down approach is taken. The root node has
probability 1. Conditional on the parental node, a mutated oﬀspring has
probability , so a direct descendant, whose genotypes are same as his parent, has
probability (1  ). Mutations are assumed to be independent. As each node only
allows one mutation, if there are N nodes in the tree, and m mutations, then the
likelihood term for mutation is m(1  )N m.
We also assume that mutation and recombinations are independent. If the
probability of a recombination is j at locus j, at one particular node, the
contribution is rj(1  j)1 r, where r indicates if there is a recombination or not.
Modeling the Mutations
Our model extends the approach of [Zöllner and Pritchard, 2005], where we had
only one possible DSL, and since we do not know beforehand which SNP-interval
it will belong to, it was assumed that without phenotype information the tree does
not contain information about the DSL.
Now, since we have multiple mutations possible, one simple extension would be
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to model P (x j T; ) = k, where k is the total number of mutations in the tree
that contribute to the disease. We still preserve the basic assumption that the tree
topology by itself does not provide any information on the causal DSLs; this will
be explained in detail in the discussion on priors (section 1.2.4).
Modeling the Disease Probability
As we have seen, the disease loci variable x contains the locations of the
mutations, its type — rare/common, and the zygosity — 0/1/2 if common, 0/1 if
it is a rare variant (as a person having two copies of the same rare variant is
extremely low, without high inbreeding). These disease mutations are distinct
from the marker SNP mutations, which are only used in making the trees.
Given a tree, a variant can be determined to be rare or common based on the
threshold — if we take MAF < 1% to be the deﬁnition of rare variants, then by
looking at where the mutation occurs in a tree, we obtain the proportion of people
who have that mutation, and simply compare it with 1%.
While modeling the rare variants, we consider the mathematically simplifying
assumption that if a subject has inherited any of the hypothetical (simulated) rare
causal mutations, that individual will be diseased, i.e. complete penetrance. With
completely penetrant rare variants, having a second rare variant in addition to the
ﬁrst one does not change the likelihood — that is the mathematical simpliﬁcation
we aim for. This is partly motivated by the standard inﬁnite-sites model [Balding
et al., 2007]. Note that this is not same as assuming that a person can have only
one rare variant.
On the other hand, a person can have multiple common variants, each with
small to moderate eﬀect. Let c be the number of common variants a person
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carries, adding over all loci in the two chromosomes. The penetrance is modeled as
a function of the common variant count c — it is easy to see that this function
should be a positive non-decreasing concave function. That is so because, it is
desirable that the gain in penetrance while moving from 20 to 21 common variants
should be rather small than while moving from 1 to 2 common variants; if we used
an additive or multiplicative instead, the change would have remained same or
even increased, something which is not desirable. It also means that we do not
enforce the common variants to have constant eﬀect sizes. A suitable model for the
penetrance is thus the power law, where p = p0  c , where p0  1 is a multiplying
factor (does not have the ‘base rate’ interpretation), c 2 (0; 1) is the standardized
count, and  2 [0; 1] is the shape parameter. In this expression, the common
variant count c is transformed to be in (0; 1) by dividing with the total number of
loci.
We also allow for phenocopy, i.e. an individual can be aﬀected without having
any causal variants. It is modeled as P (disease j no variants) = ', which is a small
but non-zero quantity.
These modeling assumptions constitute our disease model M , and the results
will certainly vary to some extent if a diﬀerent model is used. To note, M comes
only in the P ( j x;M) term.
1.2.4 Priors
We have denoted likelihoods by P (), and we denote priors by (). Following the
standard practice, we take (T ) and (x) to be uniform. As mentioned in section
1.2.3, having a uniform prior on the tree topology on absence of any speciﬁc
information is reasonable, and then our prior on the number of recombinations or
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mutations compensate for structures which have more mutations or
recombinations, because they are rare events in reality. Also, if we do not have
speciﬁc information about increased or decreased mutation rate in a speciﬁc part
of the candidate region, it would be reasonable to assume that mutation is equally
likely in any particular locus. One important point to consider is that these are
proper uniform priors. This is so because the spaces of T and x are ﬁnite, as the
number of possible minARGs is ﬁnite, and also any tree being of ﬁnite size, the
number of possible mutations is also ﬁnite.
Now we put priors on the parameters ; ; '; p0; . We do not go on to use
hyperpriors on the prior parameters, but instead choose them carefully, e.g. the
mean recombination rate from HAPMAP.
Mutation rate: () = beta(; ),
recombination: () = beta(; ).
Phenocopy: (') = beta('; ').
Penetrance: (p0) =gamma(p; p); () = log  1   ;  2 (0;1).
The mutation, recombination and phenocopy rates are probabilities, and so it is
standard to use a beta prior for them, as beta distribution is generally a conjugate
prior for probabilities. For our real data analysis, we could estimate the rates from
HAPMAP data extracted about the same region, and compute the prior
parameters. In general, the program uses standard values provided in the
literature, but since the probabilities can vary across the genomic region and the
phenocopy rate might vary based on various environmental factors, the program
allows for updated parameter values to better suit the dataset at hand. In
Bayesian methods, the priors have a larger eﬀect when the sample size is small,
and the eﬀect of the prior ’washes away’ as the sample size tends to inﬁnity. So,
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especially for smaller sample sizes, the user can choose to vary the prior
parameters themselves to see to what extent the posterior distribution is aﬀected.
The parameters p0 and  have prior distributions chosen in a way such that they
provide conjugate priors for the distribution of common variant penetrance
described in the previous section and achieve the intended ‘positive non-decreasing
concave’ shape.
1.2.5 Posterior
Because the parameters here are setwise independent, i.e. the three likelihood
terms have diﬀerent parameters, we can simplify the likelihood as (steps follow):
P (; G j x;M; f; ; '; p0; g) =
X
T
P ( j x;M; f'; p0; g)P (x j T; fg)P (T j G; fg);
which can be written concisely, by integrating out the parameters, as
P (; G j x;M) =
X
T
P ( j x;M)  P (x j T )  P (T j G):
Simpliﬁcation steps: The parameters here are setwise independent, i.e. the
the three likelihood terms have diﬀerent parameters. We will later see why this is
true. Then, we can simplify the likelihood as:
P (; G j x;M) =PT P (; G j x; T;M)P (T j x;M)
PT P ( j x; T;M)  P (G j x; T;M)  P (T j x;M) [assumption A]
=
P
T P ( j x;M)  P (G j T )  P (T j x)
=
P
T P ( j x;M)  P (x j T )  P (T j G):
Assumption A says that given the complete ancestral history of both marker
and disease loci, and given the disease model, the marker SNPs and disease
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phenotypes are independent. Which is reasonable given that the DSLs are not the
markers, and we are conditioning on the DSLs directly.
The next step follows as the model M only controls the disease probabilities.
Then we use that P (G j T ) / P (T j G)=P (T ), and P (T j x) / P (x j T )  P (T ).

As with likelihoods P () and priors (), we denote posteriors by P(). We are
interested in P(x j ; G;M).
By Bayes rule, (note that (x) is an uniform prior):
P(x j ; G;M) / P (; G j x;M)  (x) / P (; G j x;M):
Note that P (; G j x;M) can be easily obtained from the likelihood after
integrating out the model parameters. That step is much simpliﬁed by observing
again that the parameters are setwise independent, and therefore the three terms
in the likelihood can be integrated independently. (Actually,  contributes to both
tree and mutation terms. But by the construction of coalescent trees, each SNP
locus can mutate exactly once, and therefore the term involving  is same for all
trees. So we take it out of the calculations. Hence,  remains only in the mutation
term.) The details are shown next:
As mentioned in the deduction of posterior distributions, we integrate out the
model parameters from the three likelihood components. This is facilitated by the
parameters being setwise independent, which can be easily seen by looking at the
three terms.
P (T j G) =
Z
P (T j ;G)() d;
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P (x j T ) =
Z
P (x j ; T )() d;
P ( j x;M) =
Z
P ( j p0; ; '; x;M)(p0)()(') dp0 d d': 
Hence, we can write,
P(x j ; G;M) =
X
T
P (T j G)  P (x j T )  P ( j x;M):
In the ﬁnal stage, we summarize the information on mutations to the count
vector N = (Nc; Nr), which stores the number of common and rare variants
present in the case-control sample. Since are actually interested in is N , not x, so
we aggregate over x to get the posterior distribution of N .
P(N j ; G;M) =
X
T
X
x!N
P (T j G)  P (x j T )  P ( j x;M)
=
X
T
P (T j G)
(X
x!N
P (x j T )  P ( j x;M)
)
:
1.2.6 The Steps for Computation
After describing the model in the previous sections, we now outline the steps for
computing the posterior P(N j ; G;M), which is to be used for making
inferences. These steps are also illustrated on the ﬂowchart (ﬁgure 2.1) in the
beginning of this section.
1. We use SNP haplotype data (G) to generate possible minARGs (T ).
2. Given a tree (T ), we model the likelihood P (x j T ) of the putative DSL
conﬁgurations (x), which depends on the probability of mutation and
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recombination at each site.
3. Next, we model the disease probabilities, P ( j x; T;M), where  is the
disease status, M is the disease model.
4. They are used to simulate conﬁgurations of mutations (x) at probable DSLs.
Each conﬁguration corresponds to a particular count of common and rare
variants, N = (Nr; Nc).
5. So the terms in the likelihood are: P ( j x; T;M); P (x j T ); P (T j G). The
complete likelihood P (; G j x;M) aggregates the previous terms by
summing over all possible T ’s.
P (; G j x;M) =PT P ( j x;M)  P (x j T )  P (T j G).
6. We use appropriate priors, e.g. uniform prior on trees (T ), prior on
recombination rate obtained from HAPMAP, etc.
7. We evaluate posterior probabilities P(x j ; G; T;M) of such conﬁgurations
(x), given the observed phenotypes (), SNP data (G), and the tree (T ).
8. Finally, we get posteriors P(N j ; G;M) for variant conﬁgurations (N), by
aggregating over corresponding conﬁgurations, and over simulated trees.
P(N j ; G;M) =PT Px!N P(x j ; G; T;M).
The trees are generated in step 1 by Wu’s algorithm of generating minARGs
uniformly from a given haplotype data. The mutations in step 4 are generated
randomly on the branches of a given tree. Both these simulations are used for
Monte Carlo estimates of probabilities by averaging, and therefore our computed
posterior depends on the accuracy of the drawn samples — the number of draws
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and how well they span the sample space. As the sample space is ﬁnite in both
cases, ensuring these criteria are much more straight-forward.
1.2.7 A toy example
In the following simple example, we show how this method compares diﬀerent tree
structures based on their posterior (computed using likelihood and prior as
disucessed below). we ﬁx a tree and compute the posterior probabilities for
diﬀerent mutation conﬁgurations. Our data has 4 aﬀected and 5 unaﬀected
subjects. For simplicity, let
p = P(diseasej1 common variant) = 0.4,
r = P(diseasejrare variant) = 1,
' = P(diseasejwildtype allele) = P(phenocopy) = 0.1,
 = P(mutation at any node) = 0.05.
Given the tree structure, there are various possible conﬁgurations of DSLs. In
ﬁgure 1.3, we show four such scenarios.
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Figure 1.3: Some possible DSL conﬁgurations corresponding to the toy example.
First, we compute P ( j x; T;M) = P(phenotype j mutations, tree, disease
model).
1. If we had no mutations, i.e. only phenocopies;
l = ['4  (1  ')5] = [0:14  0:95]; log l =  9:7:
2. 1 common (MAF = 5/9), no rare variants;
l = [p3  (1  p)2] ['1  (1  ')3] = [0:43  0:62] [0:11  0:93]; log l =  6:4:
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3. 1 common (MAF = 5/9), 1 rare variant (MAF = 1/9);
l = [p3  (1  p)2] [r1] [(1  ')3] = [0:43  0:62] [11] [0:93]; log l =  4:1:
4. 1 rare (MAF = 1/9), no common variants;
l = [r1] ['3  (1  ')5] = [11] [0:13  0:95]; log l =  7:4:
5. 2 rare (MAF = 1/9), no common variants;
l = [r2] ['2  (1  ')5] = [12] [0:12  0:95]; log l =  5:1:
Next, we compute P (x j T ) = P(mutationsjtree).
log l /
8>>>><>>>>:
2 log(1  ) =  0:1; no mutation
log + log(1  ) =  3; 1 mutation
2 log  =  6; 2 mutations.
Combining these together, the total log-likelihood is:
log l =
8>>>>>>>>>><>>>>>>>>>>:
 9:8; no mutation (1)
 9:4; 1 common (2)
 11:1; 1common,1 rare (3)
 10:4; 1 rare (4)
 11:1; 2 rare (5).
Here, we have not evaluated all possible conﬁgurations (the ones with higher
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number of variants will have even smaller probability). Among those considered,
case (2) with one common mutation seems most likely.
1.3 Results
1.3.1 Real Data Analysis
Nonsyndromic cleft lip with or without cleft palate (NSCL/P) is a common
congenital malformation that is caused by an interplay of multiple genetic and
environmental factors [Mossey et al., 2009]. Our dataset comprises 96 NSCL/P
cases and 96 controls of Central European ethnicity in whom the exonic and
adjacent intronic regions of one candidate gene for NSCL/P has been sequenced.
The gene was among the candidate regions in an independent GWA study
[Mangold et al., 2010]. Moreover, this gene has functional importance, as it codes
for a protein which is involved in bone development, and is therefore relevant for
further analysis.
The genotypes were obtained as unphased, and the software PHASE [Stephens
et al., 2001], [Stephens and Donnelly, 2003] was used to infer the haplotypes.
Phasing probability estimates were high in general (i.e. posterior probability
computed by the software for the phase calls were mostly 100%, and in occasional
cases going down to 85%, but never below). There was a single missing SNP in a
person, and it was imputed using PHASE. The recombination rates estimated [Li
and Stephens, 2003], [Crawford et al., 2004] from the data by PHASE tally with
those from the CEU population of HAPMAP (phase II) [The International
HapMap Consortium, 2007], which comments favorably on our data quality.
On a cursory comparison of the allele frequencies between cases and controls, it
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seems that lower-frequency SNPs have comparatively higher relative diﬀerence in
terms of allele frequencies between the two groups, as compared to
higher-frequency i.e. common variants. This implies that there should be some
eﬀect from rare variants. If we graphically display the generated ARGs for the
data (a tree is shown in ﬁgure 1.4), they also imply that the top-level (i.e. higher
MAF) SNPs do not provide a good partition of the cases and controls, whereas the
lower-level SNPs provide small clusters of mostly cases and controls. These are
scenarios where our algorithm, as expected, provide higher evidence for rare
variants.
Figure 1.4: A simulated dendrogram for the dataset with cases and controls shown
corresponding to the leaves, as red and black dots respectively. Note that some
subjects have identical genotypes and therefore are grouped together.
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Figure 1.5: Smoothed posterior for real dataset. The X and Y axes denote counts
of rare and common variants, and the Z axis shows the (un-normalized) posterior
density. The density is smoothed with a Gaussian kernel.
When we look at the obtained posterior distribution (ﬁgure 1.5) for the joint
distribution of count of common and rare variants, we observe that the posterior
mode is positioned along the axis of rare variants. The posterior dies out with
increase in the number of common variants, which is expected to be the case when
there are few or no common variants. Albeit, the posterior is not highly peaked,
something to be expected given the small number of cases.
In fact, as the number of cases is only 96, the possible number of haplotypes is
only 192, therefore for rare variants with MAF < 1%, on average we expect to see
them in < 2 people. Such situations make it diﬃcult to distinguish between real
variant and phenocopy, therefore we can expect the detection eﬃciency to be low.
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But the posterior does indicate a skew towards rare variants, which is something
we expect, based on our knowledge of the data. So we can conclude that the
method works reasonably with this small sample too. In practice, as veriﬁed in our
extensive simulations, for usual case-control studies with hundreds or even
thousands of subjects, this method will have reasonably good performance.
Since we allow for phenocopy in our model, the posterior distribution also allows
for the case with no causal variants in the genomic region, i.e. the (0,0) point.
Thus, a posterior distribution comparing the presence or absence of causal variants
in that region can also be derived from the current posterior distribution. That
can lead to a statistical test for presence of causal variants, something which can
complement the objective of this current paper, which works on a genomic region
already identiﬁed as a potential candidate by a GWAS. It can be an interesting
future project.
1.3.2 Simulated Data Analysis
We conduct a simulation study for a number of diﬀerent scenarios - samples with
no underlying variants, samples with only rare variants, with only common
variants, and with both types of variants. Some (smoothed) plots of the bivariate
posterior densities are produced as examples.
The haplotype distribution is generated by drawn the haplotypes from a
coalescent genealogy via MaCS [Chen et al., 2009]. The loci are selected at
random to be the DSLs with equal probability. The disease phenotypes are
generated under various disease models (e.g. rare DSLs, common DSLs, both, or
none), from which a speciﬁed number of cases and controls are selected without
replacement. The causal loci are then excluded, following the assumption that the
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marker loci are not the DSLs. The number of SNPs is varied from 30 to 100, and
similarly the number of causal rare and common variants. The sample size is also
varied — we examine scenarios with total sample size ranging from 300 to 3000.
Although we have taken equal number of cases and controls, it is not mandatory
for our program. 1000 replications are typically used for calculating the posterior
distribution, though this number can be changed easily.
For all the ﬁgures presented here as examples, there is more spread in the
posterior distribution on the axis of rare variants, as expected; both when there
are true rare variants and when not. When there are true rare variants (ﬁgure 1.6),
the posterior is shifted towards an increased count of rare variants. Similarly, for
common variants as well (ﬁgure 1.7), the posterior is shifted more along the
common variants axis as more common variants are added while simulating the
dataset. For the scenarios presented here, we use 1000 cases and controls each, and
1000 replicates for the simulation. The data is generated as phase known.
We observe that the peakedness of the posterior increases with the increase with
sample size, which is natural, given that we get more information about the true
number of variants. This is especially true for rare variants. As mentioned in the
last section, when we have sample sizes of just a couple hundred, it is hard to
distinguish rare variants from phenocopies. Then the posterior is largely dictated
by the priors. But as we increase our sample size, given a true rare variant, we
should see a cluster of aﬀected people under some particular leaf of the genealogical
tree. That is how we get increased eﬃciency to detect the presence of rare variants.
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Figure 1.6: Posterior for simulated dataset with rare variants.
The posterior mode gives a rough idea about how many rare and common
variants there are. This can be considered as an estimate, though is bound to have
some variability, particularly in rare variants, as illustrated by the higher spread in
that co-ordinate. We can see in ﬁgure 1.8, for example, that even under no true
variant, the mode may be close to zero but not exactly zero.
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Figure 1.7: Posterior for simulated dataset with common variants.
The simulated scenario with no true variants (ﬁgure 1.8) shows what can be
considered of the null behavior for this method, where as the other cases reﬂect its
eﬃciency. While that is somewhat model and parameter-dependent, it appears
that the method does well in large samples; in the GWAS era, a sample of about a
few thousand is not unexpected.
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Figure 1.8: Posterior for simulated dataset with no variants.
Although the tree sizes increases with the sample size, the tree nodes work with
the haplotypes instead of the genotypes. And the number of possible haplotypes
will be much less that the number of people, in particular if there is LD, which we
expect to see in the small candidate regions that we work with. Thus, a moderate
increase in sample size does not incur an unreasonable increase in tree
computation.
1.4 Discussion
In this paper, we presented a method to predict the number of rare and common
variants in a genomic region underlying a complex disease. While still based on
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SNP data, we are able to obtain information on this by utilizing the genealogical
history inherent in the sample, by the use of genealogical trees (more speciﬁcally,
ancestral recombination graphs). With a Bayesian approach, we provide a
bivariate posterior distribution for the counts.
While being a Bayesian analysis, we avoid the use of Markov Chain Monte Carlo
(MCMC) or Gibbs sampling to obtain posterior distributions, by taking simple
conjugate likelihood and prior models. The choice of priors always has a scope of
debate, and might be improved if more information is available from the studies of
real datasets. For now, we try to incorporate as much available information as
possible, e.g. using the mutation and recombination rates obtained from the
HAPMAP. We think that this method can be extended by considering better
models for rare variants, which can improve upon some simplifying assumptions.
By excluding such useful but computation-intensive methods, we are able to cut
down on runtime, and the program runs under a few minutes for moderate sized
datasets, even on personal computers. To be speciﬁc, with a few hundreds of
subjects, and SNP counts around 30 to 100, the program runs in less that a couple
minutes on a laptop (2.5GHz, 3 GB RAM), when we perform 500 simulations for
each scenario. The program has fast computation speed for two reasons — ﬁrst, we
mostly use conjugate priors and are able to integrate mathematically, so we avoid
Monte Carlo integrations for many variables (and we avoid MCMC altogether) —
the computation time is mostly spent on simulating the trees and doing Monte
Carlo integration. Secondly, the total number of unique haplotypes after phasing is
much smaller than 2  the total number of subjects, so the number of tree nodes
in the ARG is much smaller than the expected number of nodes in a standard
genealogical tree. However, as the computation required for trees increases rapidly
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with large number of SNPs, this method might not be well-suited for large
datasets, e.g. a whole-genome scan, at this point; as the capability of computing
infrastructure is increasing rapidly, and sequencing costs are also going down very
fast, such extensions could become possible in the near future.
Another interesting way of extending this method would be to include
covariates. Using covariates in order to better model the environmental eﬀects, in
addition to the genetic eﬀects modeling, is becoming increasingly popular, and we
could easily extend our method to allow for environmental factors by incorporating
covariates into the phenocopy rate parameter.
At this point, we follow the standard assumption ([Wu, 2008], [Zöllner and
Pritchard, 2005]) that that haplotype phase is known or readily available. But this
method can be readily extended to include haplotype uncertainty. As the package
PHASE provides haplotype estimates along with posterior probability estimates
corresponding to those phase calls, those can easily be incorporated into our
likelihood calculations, and simulations based on diﬀerent phase conﬁgurations can
be aggregated with phasing probabilities as weights, to produce the ﬁnal posterior
probability.
The method is fairly robust to population stratiﬁcation, as it employs
genealogical trees to model the population. It will be interesting to see how this
method can be extended to family-based studies, which already contains some
useful structural information, and is believed to be more powerful for studying rare
variants.
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Rare or common? The clue’s in cluster
While analyzing complex diseases for genetic association signals via GWAS
(genome-wide association studies), it is of importance to know whether the
association signal is caused by some underlying common or rare disease variants.
In this paper, we present a new cluster-based method to analyze SNP (single
nucleotide polymorphism) data in case-control studies to obtain some insight on
this fundamental question. We extend the discovery-based cluster ensemble
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methodology by Grimmer and King [Grimmer and King, 2011] to genetic data,
since clusters can be seen to encompass genealogical trees as a particular form of
hierarchical clustering. Utilizing the structure provided by the clusters in a
Bayesian framework, we compute posterior conﬁgurations of common and/or rare
variants to predict roughly how many variants there might be underlying this
complex disease.
2.1 Introduction
It is commonly understood that complex diseases, which is the main focus of study
for genetic association studies, is driven by multiple disease variants, each
conferring small to moderate excess risk. In the early days of SNP studies, only
common polymorphisms (> 5% frequency) could be sequenced, and so the
common-disease-common variants (CDCV) hypothesis [Balding et al., 2007] was
popular. And indeed, many common variants were found to be linked with
complex diseases via GWA studies. However, as common variants could not
explain a large part of the heritability for complex diseases, rare variants were put
forward as one alternative [Dickson et al., 2010]. Coupled with the improvement in
quality in SNP data, so that rarer (> 1% frequency) polymorphisms could be
sequenced, this brought forward the interest in common-disease-rare-variants
(CDRV) hypothesis, which says that rare disease variants with higher penetrance
might underlie complex diseases.
While it has been increasingly easier to sequence and study thousands of
common variants, and to incorporate them into SNP-chips to facilitate disease risk
prediction, analyzing rare variants is still harder, as there are much fewer subjects
who carry such variants, and the error probability is higher, so detection has low
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power, and replication is diﬃcult. Thus, while analyzing a segment of the genome
for association with a complex disease, it is of importance to be able to have some
insight on whether this region contains rare or common disease variants. Such
information is useful for planning the analysis strategy — for example, if we know
that rare variants is the main factor in this region, we will need to have this region
sequenced entirely to obtain all the polymorphisms that this region carry.
Thus, we aim to answer this fundamental question, that whether a candidate
region for disease susceptibility contain rare or common variants that cause the
disease? To be able to answer this, without having to use sequence-level data for
the region, means that we need to utilize the structured information contained in
the SNP data. It has been an established technique to construct genealogical trees
to model the samples’ ancestry from the SNP data, which depicts the transmission
of mutations through generations. We observe that, a genealogical tree is simply a
particular hierarchical clustering on the set of subjects. Therefore, it is reasonable
that we seek to employ the various other clustering techniques available on this
data, and each will provide a somewhat diﬀerent way of looking into the same
data, thereby providing new angles to explore the inherent structure provided by
the SNP markers.
The question is most naturally answered by Bayesian methodology, which, by
providing a posterior on the counts of rare and/or common variants, explicitly
indicates how many variants there might be, and with how much certainty can we
make such statements. For example, we might report the posterior mode which is
P (the region contains 2 rare variants and 1 common variant) = 0:3.
In short, our algorithm is as follows — we apply the Grimmer & King clustering
methodology [Grimmer and King, 2011] on the SNP data to produce a cluster
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space. We randomly select points from this space, where each point represents a
new clustering matrix formed by local cluster ensemble of the diﬀerent clustering
methods. This point is converted into a genealogical tree by hierarchical
clustering. So, essentially, we generate a set of trees using clustering methods. To
perform a Monte Carlo integration, we then generate diﬀerent conﬁgurations of
disease mutations on these trees, and calculate the likelihood of the observed
disease status of all the subjects. The likelihood is aggregated with priors to
obtain the posterior probabilities. In the Monte Carlo step, these are aggregated
to obtain the ﬁnal posterior distribution. A ﬂowchart denoting these steps is
shown in the next section.
2.2 Material and methods
2.2.1 The cluster-selection tool of Grimmer & King
Grimmer and King develop a general-purpose clustering methodology in which
users can pick new clusters from the cluster space. Their approach is to use all the
standard clustering algorithms available and their variants (around 150), to create
a space of clustering results, where each algorithm produces its own clustering
output as a distance matrix. Therefore each output is a point in the
n2-dimensional space of all possible clusterings. The distance matrix among these
points are calculated, based on counting the number of pairs two clustering
methods assign to the same clusters.
Then a multidimensional scaling method is used to project this space into a
2-dimensional metric space. Their objective is to let the user click on any point in
this space, to generate a new cluster. Such clusters are called ‘local cluster
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ensembles’. Given any selected point in the two-dimensional space, the distance of
this point to all computed cluster points are obtained.
In the next step, an aggregated distance matrix is produced, by averaging each
pre-computed distance matrix, with weights proportional to a function of the
distance (in the 2-dim space). Usually Gaussian or Epanechnikov kernel is used.
Therefore, their method produces, given any point in the clustering space, a
similarity matrix for all the subjects, based on a weighted average of the similarity
matrices (or clusterings) given by clustering methods that are ’close’ to the given
point.
In the end, any clustering method applied on this similarity matrix will give a
clustering on the subjects, corresponding to the chosen point in the 2-dim space.
Thus, any point in the clustering space corresponds to a particular clustering of
the subjects.
2.2.2 Adopting their method for our purpose
In the tree-based approach, we randomly generated ARGs [Griﬃths and
Marjoram, 1996] for all the subjects, and used it in our calculations. But as we
said earlier, a genealogical tree is only a special case of providing a clustering. The
space in the Grimmer-King algorithm from which we can randomly pick our
clusters is a richer space, and we can use such clusters directly in our algorithm.
This is so because, each clustering matrix, when run through any hierarchical
clustering method, produces a dendrogram, which is equivalent to a bifurcating
genealogical tree. Such trees will not have recombination events marked into them.
Therefore, these trees are simpler than the ARGs.
Instead of an user clicking manually into the (visualized) 2-dimensional space,
34
we pick points randomly from that space. Therefore, we need to put a probability
distribution on the (projected) space of pre-computed clusterings. It seems that
the bivariate uniform distribution, restricted to a large rectangle containing the
convex hull of all the points, would be a reasonable choice. As we move inside the
hull, we get closer to one or the other point, and our newly selected cluster will be
give more weight to those points. So, if our selected point is close to a clustering
method, the produced cluster will have similar clustering as that. On the other
hand, if we move away from the points, towards the boundary, the weights will
become nearly equal, and therefore the new clustering matrix will be a simple
average of all the clustering matrices.
Even when we pick points randomly from this space, the space of all possible
generated clusterings is a subspace of all possible clusterings. This is because, we
are taking an weighted average of the clustering decisions made by the standard
clustering algorithms, and not from random clusters. For example, if we have four
data points f1100; 1100; 0011; 0011g, any standard clustering method will put the
ﬁrst two points in one cluster and the last two points in another. But the complete
clustering space will also have points like f(1; 3); (2; 4)g or f(1; 4); (2; 3)g. Such
points will not come into our randomly selected clusters, as the clustering
algorithms we use make ‘informed decisions’. Therefore, we can avoid picking ‘bad’
clusters.
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Figure 2.1: Flowchart for the algorithm.
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2.2.3 Computing the Posterior
The posterior computation procedure is exactly the same as the previous paper,
and is not discussed in detail here. The only diﬀerence is that, we are generating
coalescent trees (T ) directly from the simulated clusters (C), and not using ARGs
as before. Therefore, we do not need to consider recombinations any more, and the
recombination rate parameter  is out of the calculations.
2.2.4 The Steps for Computation
Here we outline the steps for computing the posterior P(N j ; G;M), which is to
be used for making inferences. These steps are also illustrated on the ﬂowchart
(ﬁgure 2.1) in the beginning of this section.
1. We use SNP haplotype data (G) to generate the clustering space by applying
the various clustering algorithms.
2. We randomly generate clustering matrices (C) by sampling points from the
clustering space.
3. Each simulated clustering matrix (C) corresponds to a genealogical tree (T )
via applying any hierarchical clustering method.
4. Given a tree (T ), we model the likelihood P (x j T ) of the putative DSL
conﬁgurations (x), which depends on the probability of mutation at each site.
5. Next, we model the disease probabilities, P ( j x; T;M), where  is the
disease status, M is the disease model.
6. They are used to simulate conﬁgurations of mutations (x) at probable DSLs.
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Each conﬁguration corresponds to a particular count of common and rare
variants, N = (Nr; Nc).
7. So the terms in the likelihood are: P ( j x; T;M); P (x j T ); P (T j G). The
complete likelihood P (; G j x;M) aggregates the previous terms by
summing over all possible T ’s.
P (; G j x;M) =PT P ( j x;M)  P (x j T )  P (T j G).
8. We use appropriate priors, e.g. uniform prior on trees (T ), prior on
recombination rate obtained from HAPMAP, etc.
9. We evaluate posterior probabilities P(x j ; G; T;M) of such conﬁgurations
(x), given the observed phenotypes (), SNP data (G), and the tree (T ).
10. Finally, we get posteriors P(N j ; G;M) for variant conﬁgurations (N), by
aggregating over corresponding conﬁgurations, and over simulated trees.
P(N j ; G;M) =PT Px!N P(x j ; G; T;M).
The clustering space and generation of clustering matrices in steps 2–3 are
performed by the Grimmer-King algorithm [Grimmer and King, 2011]. The
mutations in step 6 are generated randomly on the branches of a given tree. Both
these simulations are used for Monte Carlo estimates of probabilities by averaging,
and therefore our computed posterior depends on the accuracy of the drawn
samples — the number of draws and how well they span the sample space. As the
sample space is ﬁnite in both cases, ensuring these criteria are much more
straight-forward.
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2.3 Data Analysis
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Figure 2.2: The clustering space generated by the diﬀerent clustering methods,
projected into a two-dimensional space. The grey points correspond to the diﬀerent
methods, and the red dot is a new sampled point, corresponding to a new clustering
matrix.
We perform simulations with set-ups similar to paper 1, with similar parameter
and sample size set-ups. The basic behavior of the results is similar, as expected
— the bivariate posterior modes are able to distinguish between the null scenario,
presence of rare variants, common variants, or both, with performance being
increasingly better as sample size increases. In the following two plots, we compare
two scenarios similar to the previous paper — one where the disease is caused by
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rare variants, and in the other case, by common variants. The behavior of the
outputs is similar to the previous method, which isn’t surprising, given that the
probability models are the same — the tree structure diﬀers due to the new the
tree generation method. It seems that the posterior distribution has less variance
compared to the previous method, which could be a consequence of the clustering
algorithms picking ‘good’ clusters and therefore ‘good’ trees only (by ‘good’, we
mean trees that better approximate the underlying structure). This is discussed in
more detail in the next section.
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Figure 2.3: Posterior for simulated dataset with rare variants.
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Figure 2.4: Posterior for simulated dataset with common variants.
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2.4 Discussions
As it was remarked before, the sampled clusters are weighted combinations of
existing clustering methods, which are generally considered to be ‘good’ clustering
methods, that is, they somewhat accurately represent the underlying clustering
structure, and are not haphazard in their output. Therefore, the sampled trees are
also not exactly a uniform sample from the space of all trees, since the cluster
sampling method does not strive to enforce that — as the topology of the
clustering space is diﬃcult to express, enforcing any distribution would be diﬃcult
too. However, aggregating the posterior over these random samples would still
remain a valid procedure.
One advantage of using the clustering method over the ARGs is that we do not
need to infer the haplotypes — the genotype vectors are directly usable as inputs
for clustering. Therefore, the additional level of uncertainty introduced by the
phasing is not an issue here. On the other hand, the clustering matrix size scales
with n2 where n is the sample size, whereas the size for the previous method scaled
with the number of unique haplotypes, which is  2n and usually smaller. In
contrast, clustering only weakly depends on the number of SNPs m, while the
ARG method is much more aﬀected when m increases. So this clustering approach
will probably be more eﬃcient when applied to rare variant (i.e. sequence) data.
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3
Rare Variants? Let’s go Nonparametric.
3.1 Introduction
Genetic sequencing for complex diseases is becoming increasingly feasible,
with rapidly decreasing costs and increasing data quality. Rare variant testing
using sequencing data has therefore gained momentum in the past few years, and a
variety of diﬀerent methods has been proposed for association testing of rare
variants with complex diseases. As testing individual variants have very low
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power, as compared to Genome-Wide Association Studies (GWAS) using Single
Nucleotide Polymorphism (SNP) data, almost every test involves some sort of
collapsing of the rare variants or the test statistics into an univariate test statistic.
We propose here a new non-parametric test statistic aimed at case-control studies,
which is motivated by the well-known Kolmogorov-Smirnov non-parametric tests.
While employing a non-parametric test implies robustness, i.e. no need to to model
the data with distributional assumptions such as Gaussian or logistic models,
simulation studies show that this test does not sacriﬁce on power — it is
comparable to the standard rare variant tests currently used, in the sense that it
has similar power to test like RBT ([Ionita-Laza et al., 2011]) or SKAT ([Wu
et al., 2011]), and has better power than some other test such as C-alpha ([Neale
et al., 2011]). On the other hand, another useful corollary of using the
Kolmogorov-Smirnov structure is that it implicitly utilizes the natural ordering of
the variants on the genome. This test is designed to handle the situations when
both deleterious and protective variants are present. analytical results show some
useful features of the test statistic, and the p-value can be calculated either
mathematically or by permutation. Coupled with the ability of analytically
obtaining the p-value, the procedure is computationally extremely fast.
3.2 Materials and Methods
We start by describing the notations used in the derivation of the test. Then we
will describe the Kolmogorov-Smirnov test statistic, and present our statistic
which is a modiﬁcation of the K-S statistic aimed particularly at genetic data. In
the end, we will show some asymptotics results which enable us to compute the
p-value analytically.
45
3.2.1 Notation
Suppose we have a genomic region of length N base pairs. As N is very large, it
can also be thought of as the interval [0; 1] being discretized with a grid of size N .
Therefore, the location i corresponds to a point u = i=N in the interval.
For an individual j, the variable xji denotes if a variant is present at location i
for the jth individual. We can say that this follows a distribution function F (u),
which characterizes the probability of observing a variant at location u. We do not
make any distributional assumptions regarding the form of F (), since mutation
rates can vary across the genome.
If F1 is the distribution function for an aﬀected individual, and F0 for an
unaﬀected individual, then the basic idea is to compare F1 versus F0. Under the
null hypothesis that variants in that genomic region is not associated with the
complex trait, F1()  F0()  F (). This can be performed with a two-sample
Kolmogorov-Smirnov test, for which asymptotic distributions are known and
p-values can be computed analytically using numerical methods.
Suppose we have nX subjects as cases and nY subjects as controls. Let us use
the variable x for cases and y for controls. We deﬁne the variant counts at each
location by
xi =
nXX
j=1
xji; yi =
nYX
j=1
yji:
And we denote the cumulative counts as
Xi =
iX
l=1
xl; Yi =
iX
l=1
yl:
Note that XN denotes the total number of variants across all the subjects in cases,
and YN denotes the same in controls. Using this, the empirical CDFs obtained over
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the grid are
F^X(u)  F^X(i) = Xi=XN ; F^Y (i) = Yi=YN :
And the standard two-sample Kolmogorov-Smirnov test statistic would be
D1 = sup
1iN
F^X(i)  F^Y (i) :
3.2.2 The Proposed Test Statistic
Consider the situation where the mutation rate is the same across the entire
genomic region, but the cases have a higher variant proportion, and consequently
higher mutation rate, for each loci than the controls. This implies that the
genomic region is associated with the disease trait. However, the normalized rate
will be the same in both groups, and therefore the test statistic will not show any
diﬀerence. To be able to reﬂect this situation in the test statistic we propose the
following modiﬁcation — instead of dividing by XN in the cases, we only divide by
the total number of subjects nX , and similarly divide by nY instead of YN in the
controls. The test statistic then becomes supi jXi=nX   Yi=nY j. But unlike D1, it
is not restricted to be in [0; 1]. So we deﬁne the new test statistic to be
D = sup
i
Xi=nXK   Yi=nYK
 ; where K = max(XN=nX ; YN=nY ):
Corresponding to this, we can construct empirical CDFs
F^ X(i) =
Xi=nX
K
; F^ Y (i) =
Yi=nY
K
; 1  i  N:
Actually, only one of them is a proper CDF, in the sense that it achieves
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probability 1 at the end of its domain, and the other one is an incomplete CDF or
a subdistribution function. But we can easily extend them to become proper CDFs
by adding an extra point N + 1 to their domains and deﬁning
F^ X(i) =
8><>: Xi=nXK; 1  i  N;1; i = N + 1: ; F^ Y (i) =
8><>: Yi=nYK; 1  i  N;1; i = N + 1:
Then we can use the standard deﬁnition of a K-S statistic to deﬁne
D = sup
1iN+1
jF^ X(i)  F^ Y (i)j  sup
1iN
jF^ X(i)  F^ Y (i)j:
The previous step implies the following, which will be important later:
D  D2 =
XN=nXK   YN=nYK
 :
3.2.3 Decomposition
D = sup
i
jF^ X(i) F^ Y (i)j = sup
i
Xi=nXK   Yi=nYK
 = sup
i
F^X(i)XN=nXK   F^Y (i)YN=nYK

As the expression is symmetric in X and Y , without loss of generality assume that
K attains the maximum via X. Then,
D = sup
i
F^X(i)  F^Y (i) YN=nYXN=nX
 = sup
i
F^X(i)  F^Y (i)+ F^Y (i)1  YN=nYXN=nX
 :
) D  sup
i
F^X(i)  F^Y (i)+D2  sup
i
F^Y (i) = D1 +D2:
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So we obtain two-sided strict bounds for D:
D2  D  D1 +D2:
As one can see, the previous inequality shows that while D is similar to the K-S
statistic D1, they are not exactly equal.
3.2.4 Asymptotics for D1
To do asymptotics, we consider XN ; YN to be large, which will be so when n and
N are large. Furthermore, we require that XN and YN are of the same order. We
use the Kolmogorov-Smirnov statistic ([Kolmogorov, 1933]) — from the
asymptotics derived by Smirnov ([Smirnov, 1948], [Doob, 1949]), we know that
(conditional on XN ; YN)
r
XNYN
XN + YN
D1 ! sup jB()j;
where B() is the Brownian bridge, and the limiting distribution is called the
Kolmogorov distribution ([Donsker, 1952]). Let’s denote C = sup jB()j; the
probability distribution for C is easily computable numerically, and it is known
that for this distribution, mean C =
p
=2  ln 2 = 0:8687, variance
2C = 
2=12  2C = 0:262 ([Wang et al., 2003]).
We start by deriving the distributions of XN and YN under the null. Let
pi = P (an individual has a variant at location i). The individual pi’s are assumed
to be very small, that is, pi  0. And since N is large, we assume P =
PN
i=1 pi is
substantial. Then an appropriate model would be to take the total variant counts
of an individual j, xj =
P
i xji  Poisson(P ).
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The above deﬁnition of P assumes that variants at diﬀerent locations are
independent. Even if not, as long as the individual pi’s are small, a Poisson(P )
model is a valid model for some general P estimated from the data.
Then, under the null, every individual is i.i.d., and by CLT,
p
nX(XN=nX   P ) d! N(0; P );
p
nY (YN=nY   P ) d! N(0; P ):
Let us deﬁne n = nX + nY . Let c = 2nX=n, c = 2nY =n, and deﬁne  = P  n=2. If
the sample sizes are equal, c = c = 1. With this, we can approximately write,
XN = XN=  N(c; c=); YN = YN=  N(c; c=):
Or, with the CLT notation, as cases and controls are independent, we have
p

0B@
0B@ XN
YN
1CA 
0B@ c
c
1CA
1CA d! N
0B@
0B@ 0
0
1CA ;
0B@ c 0
0 c
1CA
1CA :
Now we work with D1. Conditional on XN ; YN , we have seen that D1 ! A  C,
where
A =
r
XN + YN
XNYN
=
1p

s
XN + YN
XN YN
=
1p

r
1
XN
+
1
YN
:
Applying the multivariate delta theorem on the previous expression, we get
p

r
1
XN
+
1
YN
 
p
2k

d! N

0;
1
4

1
c2
+
1
c2
  1
cc

;
where k = 1
2

1
c
+
1
c

. Note that k is the inverse of the harmonic mean of c and c,
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and therefore by the A.M.  G.M.  H.M. inequality, k  1. When we have equal
sample sizes for both cases and controls, k = 1, and
p

r
1
XN
+
1
YN
 
p
2

d! N

0;
1
4

:
This implies, p
 
A 
p
2kp

!
P! 0. Recall that, as n is large, we consider  to be
large as well.
So, comparable to the one-sample notation of pnDn ! C, we get
p
D1  1p
2k
! C.
3.2.5 Asymptotics for D2
D2 =
 XN=nX   YN=nYmax(XN=nX ; YN=nY )
 :
We deﬁne ~XN = XN=(nX  P ) = XN=(c  ) = XN=c. Similarly
~YN = YN=(nY  P ) = YN=c. Then, using the previous asymptotic expression,
p

0B@
0B@ ~XN
~YN
1CA 
0B@ 1
1
1CA
1CA d! N
0B@
0B@ 0
0
1CA ;
0B@ 1=c 0
0 1=c
1CA
1CA :
From the denominator of D2, we can see that we need the joint distribution of
order statistics. Suppose X1; X2 are two independent Gaussian variables with
mean 0, and their variances are a; b respectively. Let Z1; Z2 be the two order
statistics, Z1 the minimum and Z2 the maximum. Then, we know that,
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([Nadarajah and Kotz, 2008], [Jones, 1948]),
E(Z2) =  E(Z1) =
p
a+ bp
2
;Var(Z2) = Var(Z1) =
1
2

1  1


(a+b);Cov(Z1; Z2) =
1
2
(a+b):
Here, if we deﬁne Z1; Z2 to be the two order statistics corresponding to ~XN ; ~YN , we
have
p

0B@
0B@ Z2
Z1
1CA 
0B@ 1 +
p
kp

1 
p
kp

1CA
1CA d! N+
0B@0; k
0B@ 1  1 1
1

1  1

1CA
1CA :
Note: here we are using the notation N+ because the distribution only has support
in the region Z2  Z1.
In this set-up, D2 = 1  Z1Z2 . So, we use the multivariate delta theorem to obtain
p

 
Z1
Z2
 
p
 pk
p
+
p
k
!
d!
N+
0@0; k
(
p
+
p
k)2
24(   1)  2p pkp
+
p
k
+ (   1)
 p
 pk
p
+
p
k
!2351A :
As  is large, we can ignore the higher order terms in the variance to simplify the
expression. This leads to
D2  N+
 
2
p
k
p
+
p
k
; (2   4) k
(
p
+
p
k)2
!
or
p
D2  N+
 
2
r
k

; (2   4)k

!
:
Here too we use N+ to denote the fact that this distribution is truncated at 0.
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3.2.6 Testing from a Truncated Normal
An important point we need to remember is that, both components of D are
truncated at 0, and in particular, the distribution of D2 is a truncated normal
distribution ([Barr and Sherrill, 1999]). So, its derived expectation and variance
are under truncation as well. For example, if X  N(; 2), and Y is X truncated
at a, then
E(Y ) =  = +;Var(Y ) = 2 = 
2(1+ 2); where  = a  

;  =
()
( ) :
The mean and variance derived in the asymptotics above are actually  and .
From these, the original  and  can be obtained numerically.
Then, we can do a one-sided test by obtaining a cut-oﬀ  for the upper tail, such
that
 = +  1 (0:95 + 0:05()) :
3.2.7 Behavior of the Test Statistic
The derivation shows that the test statistic is controlled by two diﬀerent
components — the Kolmogorov-Smirnov statistic D1 depending on the diﬀerence
in the way variant proportions are distributed among cases and controls, and the
statistic D2 taking care of the overall diﬀerence in variant counts. Under the null
both terms have an equal eﬀect — pD1 and pD2 both have distributions of
same order. On the other hand, diﬀerent alternative scenarios will lead to diﬀerent
components dominating the test statistic. If there is a diﬀerence in the number of
variants among the two groups, D2 will dominate, and the test asymptotically will
have power 1 as sample size goes to inﬁnity. Even if not, as long as there is a
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diﬀerence between variant proportion distribution in the two groups, the presence
of D1 will still lead the asymptotic power towards 1.
For example, consider the situation of n = 2; N = 5, and the observed x vector
is (0; 1; 0; 0; 0), and y = (0; 0; 1; 0; 0). Then, XN = YN = 1, so that D2 = 0. But
F X = (0; 1; 1; 1; 1) and F Y = (0; 0; 1; 1; 1), so that D = 1. Here, the entire
contribution comes from the Kolmogorov-Smirnov part. In this case, therefore, the
statistic successfully distinguishes between the cases, which have a deleterious
variant at location 2, and controls, which have a protective variant at location 3.
In the following two diagrams (3.1, 3.2), we illustrate the two situations where
the test statistic will be powerful. The null situation is presented in the third
diagram (3.3) for comparison.
Figure 3.1: Example 1: Cases and controls have diﬀerent mutation rates.
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Figure 3.2: Example 2: Cases and controls have similar mutation rates overall, but
the mutation regions are diﬀerent.
Figure 3.3: Example 3: No diﬀerence between mutation rates in cases and controls.
This is also shown in the next two simulations results — the ﬁrst scenario (3.4)
is where the mutation rates are diﬀerent, and in the second scenario (3.5), cases
and controls have diﬀerent mutation rates in clusters. On the left, the case and
control CDF’s are shown, and on the right, the permutation distribution of the
test statistic is shown. The red star denotes the observed value of the test statistic,
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and the magenta circle denotes the 5% cut-oﬀ.
Figure 3.4: Example 1: Case and control mutation rates are diﬀerent.
Figure 3.5: Example 2: Cases and controls have mutation rates varying in two
separate clusters.
The asymptotics for D1 assumes continuity for the underlying probability
distribution, i.e. pi’s are very small. This is ensured by the rare variant
assumption. Moreover, common variants lead to a large jump in the empirical
CDF, irrespective of whether it is causal or not. So we have decided to remove all
56
the variants with MAF > 1% from the data. Although having only rare variants
does not exactly imply the continuity assumption — every variant does not occur
in an unique location — but that is not a serious issue. Even if the underlying
mutation distribution has discrete mass at some points, it has been shown that the
Kolmogorov-Smirnov test is still a valid test under such circumstances, while being
conservative ([Conover, 1972]). It is also known that for large data size, the loss in
power is not very large ([Horn, 1977]), especially when the individual probabilities
are not large, which will be the case when we remove the common variants.
Due to the presence of  in the asymptotics, which involve the mutation rate P ,
this test is no longer an exactly nonparametric test. But that is acceptable,
because mutation rate is an important parameter, and diﬀerence in mutation rates
is precisely the reason why we modiﬁed our statistic to be diﬀerent from the
standard Kolmogorov-Smirnov statistic. Even though it is not exactly
nonparametric anymore, the test still retains most of the robustness properties of
the Kolmogorov-Smirnov test — it still does not make any distributional
assumptions about the mutation rate across the genomic region, neither about the
LD pattern, nor about eﬀect sizes/directions.
3.3 Comparison to Other Rare Variant Tests
In order to avoid the burden of high dimensionality, most rare variant tests apply
pooling of some sort. The collapsing-based Cohort Allelic Sums Test (CAST)
([Morgenthaler and Thilly, 2007]) and Combined Multivariate and Collapsing
(CMC) method ([Li and Leal, 2008]) were among the ﬁrst to address the rare
variants issue speciﬁcally, and there have been many other proposed tests, each
designed to take advantage of a particular situation, with particular models and
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assumptions. For example, the Replication-Based Test (RBT) method
([Ionita-Laza et al., 2011]) assumes Poisson probability models for variant counts
at each loci; the Sequential Kernel Adaptive Test (SKAT) method ([Wu et al.,
2011]) uses logistic regression to model the disease probability given each variant
(the weighted combination of individual logistic score tests is equivalent to a
overall variance component score test). [Asimit and Zeggini, 2010], [Bansal et al.,
2010], [Basu and Pan, 2011] are some good reviews of the various rare variant
methods proposed over time. It is worthwhile to mention that there are also some
Bayesian approaches to rare variant analysis ([Shen et al., 2011]), even if those are
not as popular, and are generally not covered by these review papers.
While tests like CMC combine the variant genotypes directly, other tests such as
SKAT combine individual test statistics (scores or variances) corresponding to the
variants. According to a review by [Pongpanich et al., 2012], neither method is
uniformly the best — genotype collapsing is more sensitive to presence of noise
(non-causal loci), while score collapsing is more robust to variations in eﬀect sizes,
association directions, MAFs, and LD.
Recently, it was highlighted that rare variants can have eﬀects in both directions
— some could be harmful and some could be protective towards the disease.
Therefore, newer tests were designed which would remain powerful under such
scenarios. The test we propose is also motivated by that fact, and this is where the
robustness of the Kolmogorov-Smirnov method is eﬀective — no speciﬁcation of
the underlying variant distribution is necessary.
Frequently, weights are used in the test statistics to up-weight the rare variant
contributions — e.g. the Weighted-Sum method ([Madsen and Browning, 2009])
uses weights inversely proportional to the standard deviation under the binomial
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model, i.e. w = 1=
p
p(1  p) where the MAF p is generally estimated from the
controls. [Price et al., 2010] showed that using such an weight function implies this
assumption on the log odds ratio of the disease — log(OR) / 1=pp(1  p). The
SKAT method uses heuristic weights derived from beta distributions with MAF as
the parameter, and the RBT method uses Poisson probability of the rare variant
counts as weights.
Some tests are generalized to include covariates or interaction terms, and some
are applicable to quantitative traits as well. At this point, we do not extend our
test to those directions.
In this paper, we compare our method to the C-alpha test ([Neale et al., 2011]),
RBT ([Ionita-Laza et al., 2011]), and SKAT ([Wu et al., 2011]). Among the more
well-known tests, we do not consider the CMC ([Li and Leal, 2008]), Kernel
Machine Regression (KMR) method ([Liu et al., 2008]), Kernel-Based Adaptive
Cluster (KBAC) method ([Liu and Leal, 2010]), Step-up method ([Hoﬀmann et al.,
2010]), Variable Threshold (VT) test ([Price et al., 2010]). We chose to compare to
those tests because they allow for variant eﬀects in both directions.
In the review by [Basu and Pan, 2011], they provide simulation results showing
power calculations for various test statistics. We are only interested in the part
where eﬀects in both directions are considered — otherwise, as expected, simple
genotype collapsing methods perform the best. They did not consider the SKAT
and VT methods; among the rest, KBAC, KMR, C-alpha and RBT were the best
performers, and had similar powers even though they are based on diﬀerent
approaches — genotype vs. score collapsing. Since they had similar performances,
we chose to only consider C-alpha and RBT, each representing a diﬀerent
collapsing approach.
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3.4 Application to Real Data
Nonsyndromic cleft lip with or without cleft palate (NSCL/P) is a common
congenital malformation that is caused by an interplay of multiple genetic and
environmental factors [Mossey et al., 2009]. Our dataset comprises 96 NSCL/P
cases and 96 controls of Central European ethnicity in whom the exonic and
adjacent intronic regions of one candidate gene for NSCL/P has been sequenced.
The gene was among the candidate regions in an independent GWA study
[Mangold et al., 2009]. Moreover, this gene has functional importance, as it codes
for a protein which is involved in bone development, and is therefore relevant for
further analysis.
There was a single missing SNP in a person, and it was imputed using PHASE
[Stephens et al., 2001], [Stephens and Donnelly, 2003]. The recombination rates
estimated [Li and Stephens, 2003], [Crawford et al., 2004] from the data by
PHASE tally with those from the CEU population of HAPMAP (phase II) [The
International HapMap Consortium, 2007], which comments favorably on our data
quality.
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Figure 3.6: The case and control allele frequency distributions for the real data.
The bin locations for this histogram are the speciﬁci allele frequencies, and for each
particular allele frequency the height of the bar denotes the number of subjects who
have a variant with that allele frequency. Red denote cases and blue denote controls.
The lowest allele frequency corresponds to variants which are present only once in
96 subjects (0.5%) — we have 8 such loci in cases, and 1 in controls. In the middle
region, we can see common variants which diﬀer in allele frequencies in cases and
controls — the location of the red and blue bars are diﬀerent.
On a cursory comparison of the allele frequencies between cases and controls
(3.6), it seems that lower-frequency SNPs have comparatively higher relative
diﬀerence in terms of allele frequencies between the two groups, as compared to
higher-frequency i.e. common variants. This implies that there should be some
eﬀect from rare variants. But as the number of cases is only 96, for rare variants
with MAF < 1%, on average we expect to see them in  2 people. On the other
hand, with only 27 SNPs, the number of rare variant loci is low as well. Overall,
this implies a high signal-to-noise-ratio, and therefore low power for association
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detection. Still, our test statistic shows signiﬁcant association between the disease
status and rare variants, which is something we expect to see, based on our
knowledge of the data. So we can conclude that the method works reasonably with
this small sample too.
With only the rare variants selected, we compare our method to the three
diﬀerent methods mentioned in the previous section and show the corresponding
p-values in the table below. As this test has the lowest p-value, it might be the
case that this test has more power for this situation, although we can not make a
general statement with just one dataset.
Method P-value
K-S test 0.04
RBT 0.20
SKAT 0.43
C-alpha 0.50
3.5 Simulation Study
3.5.1 Simulation Set-up
We use detailed simulations to compare the power of our test statistic to the
C-alpha, RBT and SKAT methods. There are a huge variety of simulation
methods in practice, with almost every paper having their own simulation method,
and in general the simulation set-ups correspond to the model assumptions in the
test statistic, e.g. logistic link function for disease probabilities when logistic
regression model is used in the test. To accommodate this, we use not one but two
simulation scenarios:
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1. In the set-up of [Basu and Pan, 2011], [Pan, 2009], they use a multivariate
normal distribution Z = (Z1; : : : ; Zm) as latent variables for the genotypes.
A ﬁrst-order autoregressive (AR1) covariance structure is used:
Corr(Zi; Zj) = 
ji jj, with  varied from 0 to 0.9. For each loci, these are
dichotomized using a quantile obtained from a desired MAF (randomly
generated to be  1%) value to produce the genotypes X = (X1; : : : ; Xm).
With chosen parameters  = (1; : : : ; m), they used a logistic model
logit P (Y = 1) = 0 +X
0 to generate the disease status. Some components
in  are set to 0 to represent non-causal loci, while some are positive and
some negative, to indicate diﬀerent association directions. As logistic and
probit models are quite similar, we chose to use the probit link instead, as it
makes simulations easier.
2. The previous simulation method is simplistic in the sense that it does not
consider population genetics models like coalescent genealogy or the
Wright-Fisher allele frequency distribution model [Balding et al., 2007]. As
some simulation studies ([Ionita-Laza et al., 2011], [Price et al., 2010]) use
such models to generate data, we considered it as an alternative simulation
scenario. Speciﬁcally, we used MaCS (Markovian Coalescent Simulator,
[Chen et al., 2008]) to simulate genomic sequences under coalescent model
with a Markov process. Standard demographic parameters, as discussed in
([Price et al., 2010], [Chen et al., 2008]) were used. Then, with randomly
generated eﬀect sizes for selected causal loci, the overall disease risk of an
individual is calculated by summing over all the loci, and then the disease
status is generated by a Bernoulli model.
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Sample size is varied from 300 to 1500 cases, and an equal number of controls.
Number of loci is varied from 10 to 100, and the number of causal loci is varied
accordingly. Eﬀect sizes and other simulation parameters were also varied. We
consider ﬁve diﬀerent parameter set-ups to include the diﬀerent situations:
1. Simulation under the null,
2. Under the alternative of only harmful variants,
3. Under the alternative of both protective and deleterious variants,
4. Protective and deleterious variants in separate zones on the genomic region,
5. With causal common variants in addition to the causal rare variants.
3.5.2 Simulation Results
Firstly, we veriﬁed that the test maintains the proper alpha level — when tested at
5% level under the null in our simulations, the rejection rate never exceeded 5%.
This is also shown and explained in ﬁgure 3.8.
Now we show the behavior of this K-S test statistic while varying diﬀerent
simulation parameters. First, we show how the power increases as sample size is
increased. In 3.7, the X-axis shows the sample size in cases (we took equal sample
size in controls) versus the power of the test, for a ﬁxed number of variant loci – 15
– out of which 3 are causal. The standard Neyman-Pearson testing scenario has
power growing with sample size as the order of pn, and we see a similar
relationship here.
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Figure 3.7: Plot of power versus sample size.
Next, we show how the power increases as the number of causal variants
increase. In the next ﬁgure (3.8), we consider the scenario with 500 cases and 500
controls, and 15 loci. The number of causal variants among these 15 is varied from
0 to 7. At 0, this represents the level of the test, which is 5%. And when we have
around half of the variants to be causal, the power reaches 1.
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Figure 3.8: Plot of power versus number of causal variants.
It is intuitive that if we vary it the other way — if we keep the number of causal
loci ﬁxed but increase the total number of loci, then we will lose power, because
the increasing number of non-causal loci will wash away the contribution of the
causal loci to the test statistic. This is also discussed in [Pongpanich et al., 2012]
as a common issue in rare variant testing, and it is observed that this is more of a
problem in genotype-based collapsing methods. In ﬁgure 3.9, we again consider
500 cases and 500 controls, and ﬁx 5 rare variants to be causal. Then, we vary the
total number of loci from 5 (i.e. all variants are causal) to 100. The decrease in
power is shown in the graph.
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Figure 3.9: Loss of power as number of non-causal variants increase.
It was discussed earlier that, being location-based, this test will gain power when
harmful and protective variants are clustered together on the genome, rather than
having random locations. In the next ﬁgure (3.10), we show the power gain (via
ratio) of the test when simulations are performed with random locations of causal
variants versus when variants of same eﬀect directions are clustered. The sample
size is varied from 300 to 1500. As expected, the power in both situations tend to
1 as sample size increases, and so the ratio decreases with increase in sample size.
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Figure 3.10: Gain in power when harmful and protective variants are cluster in
separate regions on the genome.
Lastly, we compare the performance of this statistic with the three other rare
variant testing methods (RBT, C-alpha and SKAT) via simulation study. We ﬁx
500 cases and 500 controls, and 10 variant loci at random. Then, we vary the
number of causal variant loci from 1 to 7, and as expected, the power increases for
all the tests. In the graph (3.11), we see that the power of the K-S test is always
comparable to the RBT and SKAT tests, which were found to be among the more
powerful tests in the review papers. The power of the C-alpha test does not seem
to grow as fast as the other three tests.
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Figure 3.11: Comparing power for the diﬀerent rare variant tests.
3.6 Discussion
We have presented a modiﬁcation of the Kolmogorov-Smirnov test suitable for rare
variant association testing. It is a robust, nonparametric test, able to work with
variant eﬀects in both directions, and any mutation distribution. We compared
this method to three well-known rare variant tests, covering both genotype-based
and score-based collapsing methods. It is seen that the method has similar power
compared to the other rare variant tests in various situations, and as expected
from the structure of the test, does well when variants of diﬀerent eﬀect directions
are clustered separately.
As mentioned in the review by [Pongpanich et al., 2012], genotype collapsing
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methods such as this one is more sensitive to increasing number of non-causal loci.
However, as we do not up-weight the rarer variants, this means that most noise is
not up-weighted, and therefore the power loss is not very high. The robustness of
the Kolmogorov-Smirnov method also helps in this regard. Overall, this method
compares favorably to the RBT or SKAT method, and often performs better than
the C-alpha test.
Due to the structure of the Kolmogorov-Smirnov test, this method would be
most powerful when variants with same eﬀect directions occur together on the
genomic region. This is an unique feature of this test, in contrast to the previous
test statistics, which are independent of the variant locations. As expected, this
test gains power under such scenarios. And that might have a genetic basis,
especially when functional information form bioinformatics is borrowed. Even
when the location ordering of harmful and protective variants are mixed, the test
still has decent power.
Finally, it is computationally very fast, and analytical p-values are available.
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